Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia

Ibrutinib is a covalently binding inhibitor of the B-cell receptor signaling-mediator Bruton’s tyrosine kinase (BTK) with great efficacy in chronic lymphocytic leukemia (CLL). Common side effects like atrial fibrillation (AF), bleeding and infections might be caused by ibrutinib’s inhibition of othe...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tom A. Mulder, Lucía Peña-Pérez, Anna Berglöf, Stephan Meinke, H. Yesid Estupiñán, Kia Heimersson, Rula Zain, Robert Månsson, C. I. Edvard Smith, Marzia Palma
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2021-05-01
Colecção:	HemaSphere
Acesso em linha:	http://journals.lww.com/10.1097/HS9.0000000000000564
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!